Dang et al. discover carvedilol, a clinically approved β-adrenergic receptor antagonist, as a STING activator through high-throughput screening. Mechanistically, carvedilol promotes STING dimerization to enhance type I interferon responses. The findings provide the basis for repurposing carvedilol in the therapy of STING-related diseases.